Clever Culture Systems (ASX:CC5) said it received a purchase order for an APAS Independence instrument from Novo Nordisk in Europe, and the Danish firm will assess the suitability of the technology for use across their manufacturing network, according to a Monday Australian bourse filing.
The evaluation will assess the performance of both 90 millimeter and contact plate analysis modules for the reading of culture plates used in pharmaceutical environmental monitoring.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.